Fatal course after administration of rituximab in a boy with relapsed all: a case report and review of literature

Charite, Universitatsmedizin Berlin, Germany. georg.seifert@charite.de

We are reporting on a 14-year-old boy with a very early relapse of pre-B acute lymphoblastic leukemia (ALL) and anaplastic astrocytoma WHO degrees III; the astrocytoma was subtotally resected and subsequently treated with irradiation and chemotherapy. The leukemic relapse was refractory to the administered salvage therapy. Therefore, treatment with the human anti-CD20 monoclonal antibody (MoAb) IDEC-C2B8 (rituximab) was initiated. After a small fraction of the standard dose (375 mg/m(2)) had been administered, the infusion had to be interrupted because of an acute attack of pain in the lumbar region. Two days later, after resumption of the therapy, he developed a fatal course of systemic inflammatory response syndrome (SIRS) and died, possibly due to uncontrollable cytokine release syndrome associated with sepsis. The fatal course will be discussed based on a review of the literature.

This article has been cited by other articles:

				S. Lovric, U. Erdbruegger, P. Kumpers, A. Woywodt, C. Koenecke, H. Wedemeyer, H. Haller, and M. Haubitz Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients Nephrol. Dial. Transplant., January 1, 2009; 24(1): 179 - 185. [Abstract] [Full Text] [PDF]